Pharma giant Jazz dismisses final patent claim involving cannabinoid epilepsy drug

On: February 11, 2025

Global pharma company Jazz Pharmaceuticals has ended patent claims related to its cannabinoid-based epilepsy drug, Epidiolex.

Pharma giant Jazz dismisses final patent claim involving cannabinoid epilepsy drug is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs

Read More: Pharma giant Jazz dismisses final patent claim involving cannabinoid epilepsy drug

Previous Post: Michigan governor floats extra 32% adult-use cannabis tax to fund roads

Next Post: Hawaii Senate Panel Approves Bill To Increase Amount Of Marijuana That’s Decriminalized Under State Law

Comments are closed, but trackbacks and pingbacks are open.